In a world where veterinarians demonstrate unwavering compassion, dedication, and confront remarkable challenges daily, two exceptional individuals are stepping into the spotlight to shine a much-needed light on the profession. Dr. Jen Remnes and Dr. Jess Trice, co-owners of Vetique Chicago, are embarking on a groundbreaking venture with their new show, "REAL TALK with Dr. Jenn and Dr. Jess." This series is set to revolutionize the way we perceive and discuss the experiences and issues facing veterinary professionals today.

Vet Candy, a prominent platform for veterinary education, has launched a groundbreaking continuing education program, "Unmasking the Opioid Crisis: A Veterinary Professional's Role Revealed." This comprehensive program equips veterinary professionals with knowledge and tools to combat the opioid crisis and underscores their vital role in addressing this national concern. It includes expert-led podcasts, insights into opioid use history, and the responsibilities of veterinarians in responsible opioid prescribing. Dr. Jill Lopez, CEO of Vet Candy, emphasizes the program's importance for all veterinary professionals, regardless of state requirements, as it addresses a critical issue impacting both humans and animals. This program is offered for free and aims to make a significant impact in the veterinary community.

Zoetis Inc. (NYSE: ZTS) reported its financial results for the third quarter of 2023 and updated its guidance for full year 2023.

The company reported revenue of $2.2 billion for the third quarter of 2023, an increase of 7% compared with the third quarter of 2022. On an operational1 basis, revenue for the third quarter of 2023 increased 8% compared with the third quarter of 2022, excluding the impact of foreign currency. Net income for the third quarter of 2023 was $596 million, or $1.29 per diluted share, an increase of 13% and 14%, respectively, on a reported basis.

Adjusted net income2 for the third quarter of 2023 was $629 million, or $1.36 per diluted share, an increase of 11% and 12%, respectively, on a reported basis, and an increase of 13%and 15%, respectively, on an operational basis. Adjusted net income for the third quarter of 2023 excludes the net impact of $33 million for purchase accounting adjustments, acquisition-related costs and certain significant items.